Abstract
New Nucleosides, analogues derived from 1, 3, 4-oxadiazole, arylidene analogues and α-aminophosphonate were prepared. Infrared (IR), elemental analysis and 1HNMR elucidated nucleosides; arylidines and phosphonate derivatives. The prepared derivatives were purified and allowed to test against bacteria strains. Phosphonate derivative 12a showed the higher antibacterial against E. coli with inhibition zone 35 mm, P. aeruginosa with inhibition zone 30 and S. aureus with inhibition zone 22 while compounds 4, 6d, 9a, 9c and 12c showed moderate to weak activity against these bacteria species with inhibition zones ranged from 12 mm to 24 mm. The molecular docking studies was applied on compound 12a, which showed the binding at the active DNA Gyrase.
Keywords: 4-Nitrophenol, Nucleosides, Arylidene derivatives, α-aminophosphonate derivatives, Molecular docking, Antibacterial activity
1. Introduction
Analogues of nucleoside are used as antibiotics as antiviral strains to treat cancer have been source of investigation for therapies and drug development to treat cancer and other pathogens (Jordheim et al., 2013). They possess properties of anticancer, antiviral and antibacterial (Ding et al., 2010). The main components of deoxyribonucleic acid and ribonucleic acid are nucleotides, It consists of nucleosides and phosphate group, also responsible for the production of proteins, also responsible for the production of proteins, acts as cofactor in many metabolic pathways; lipid and polyamine biosynthesis (Yssel et al., 2017). Nucleosides are metabolites excreted from RNA, composed of nucleobases which are covalently attached to ribose or deoxyribose. The aromatic heterocyclic nucleobases contain nitrogen in the ring with purine or pyrimidine. (Dudley, 2009). All pro-drugs derived from nucleoside are undergo chemical modification, to add phosphorous group to activate sites in many cellular processes during nucleotide and nucleic acid metabolism (Tsesmetzis et al., 2018). Development of nucleoside-analogue; Acyclic nucleosides such as zidovudine (AZT), Didanosine (DDL) and Zalcitabine (ddC) were effective antiviral analogues used for treating human immunodeficiency virus (HIV) infection but due to its toxicity has led to desertion (Seley-Radtke & Yates, 2018). Phthalazines heterocycle containing nitrogen is a novel drug possess antitumor, antihypertensive and antidiabetic activities (Sangshetti et al., 2019, EL-Hashasha et al., 2017, Haikal et al., 2003, Demirayak et al., 2004, Lenz et al., 2002, Dogruer et al., 2004, Watanabe et al., 1998). Purine and Pyrimidines as nucleotides and nucleosides are energy carriers show various bioactivity such as bactericidal, fungicidal, insecticidal properties (Thomson & Lamont, 2019).
2. Material and methods
2.1. Chemistry
Melting points were analyzed on kofler block apparatus and were uncorrected 1HNMR was recorded on spectrometer (400 MHz), chemical shifts are referenced from tetramethylsilane (TMS) δ 0.00, as internal standard, using CDCl3 as a solvent for 1H. Fourier transform infrared (FT- IR) Spectroscopy were performed by means of ic50 model FTIR (Thermo) using KBr disks. Mass spectra were obtained using GC–MS, TLC using aluminum silica gel plates 60 F245 monitored the progress of the reactions. The antibacterial activity of the synthesized compounds was carried out at well- maintained Biology Lab.
2.1.1. Ethyl 2-(4-nitrophenoxy) acetate (2) (Amer et al., 2018)
Equivalent amounts of 4-nitrophenol (1) (1.39 gm, 0.01 mol), ethylchloroacetate (1.225 gm, 0.01 mol) and K2CO3 (1.38 gm, 0.01 mol) were dissolved in 50 ml of acetone and then, refluxed for 6 h. The solvent evaporation took place at low pressure. The final product was collected, dried and cleaned to yield 92% of a yellow powder. m.p. 221–222 °C. Rf = 0.45 (3% CH3OH: CHCl3).1H NMR (CDCl3): d = 1.18 (3H, t, J = 7.2 Hz, CH3CH2), 4.33 (2H, q, J = 7.2 Hz, CH3CH2), 4.75 (2H, s, CH2), 7.55 (2H, d, J = 5.5 Hz, H-2), 8.30 (2H, d, J = 4.9 Hz, H-3); MS: m/z(%) 226 (M++ H).
2.1.2. 2-(4-Nitrophenoxy) acetohydrazide (3) (Amer et al., 2018)
Equivalent amounts of 2 (2.25 gm, 0.01 mol) and hydrazine hydrate (1.5 gm, 0.03 mol) were dissolved in 40 ml ethanol and then, refluxed for 10 h. Solvent has been evaporated by halving it and put in the fridge one day; A white powder was collected in order to yield 95% of the resulting product, m.p. 186–188 °C. Rf = 0.45 (5% CH3OH in CHCl3). IR spectra (KBr) (v,cm−1): 3460, 3505 (NH2), 3345 (NH), 1645 (CO); 1HNMR (CDCl3): d = 2.65 (2H, brs, NH2), 4.63 (2H, s, CH2),7.35 (2H, d, J = 5.5 Hz, Ar-AH), 8.22 (2H, d, J = 4.9 Hz, Ar-H), 8.53 (1H, brs, NH); MS: m/z (%) 211 (M+).
2.1.3. 4-(5-((4-nitrophenoxy) methyl)-1, 3, 4-oxadiazol-2-yl) aniline (4)
Equivalent amounts of hydrazide 3 (2.11 gm, 0.01 mol) and p-aminobenzoic acid (1.37 gm, 0.01 mol) were dissolved in 20 ml phosphorousoxychloride and then heated in the presence of condenser for 20 h. The final blend has been poured on 100 g ice; the sample was collected and dried for 70% yield of brown crystal, m.p. 245–247 °C. Rf = 0.75 (10% CH3OH in CHCl3). IR spectra (KBr) (v,cm−1): 3460, 3505 (NH2), 1645 (CO); 1HNMR (CDCl3): d = 4.60 (2H, s, CH2), 6.05 (2H, brs, NH2), 6.56 (2H, d, J = 5.5 Hz, Ar-H), 7.20 (2H, d, J = 4.9 Hz, Ar-H), 7.50 (2H, d, J = 5.5 Hz, Ar-H), 8.10 (2H, d, J = 5.5 Hz, Ar-H), 8.53 (1H, brs, NH); MS: m/z (%) 312 (M+).
2.1.4. Synthesis of arylidene derivatives 6a-d
Equivalent amounts of 4 (3.12 gm, 0.01 mol) and aromatic aldehydes (1.56 gm, 1.22 gm, 1.40 gm and 0.96 gm, 0.01 mol respectively) were dissolved in 40 ml ethanol; the addition of few drops of AcOH catalyst was occurred directly and then the blend was refluxed for 10 h. The resulting product has been purified to produce a yield of 6a-d (90–93%).
2.1.4.1. N-(naphthalen-1-ylmethylene)-4-(5-((4-nitrophenoxy) methyl)-1, 3, 4-oxadiazol-2-yl) aniline (6a)
Brown powder, 90% yield, m.p. 175–177 °C Rf = 0.55 (5% CH3OH: CHCl3). IR spectra (KBr) (v, cm−1):, 3070 (aromatic), 2995 (aliphatic), 1572, 1380 (NO2), 1465 (CH2); 1HNMR (400 MHz, CDCl3): d = 4.82 (2H, s, CH2), 7.22–8.14 (15H, m, CH aromatic), 8.50 (1H, s, CH); MS: m/z (%) 450 (M+).
2.1.4.2. N-(2-hydroxybenzylidene)-4-(5-((4-nitrophenoxy)methyl)-1,3,4-oxadiazol-2-yl)aniline (6b)
White powder, 92% yield, m.p. 205–207 °C Rf = 0.45 (5% CH3OH : CHCl3). IR spectra (KBr) (v, cm−1): 3250 (OH), 3050 (Ar-H), 2990 (CH aliphatic),1575, 1385 (NO2), 1650 (CH2); 1HNMR (400 MHz, CDCl3): d = 4.82 (2H, s, CH2), 5.40 (1H, brs, OH), 7.00–8.12 (12H, m, CH aromatic), 8.65 (1H, s, CH); MS: m/z (%) 416 (M+).
2.1.4.3. N-(4-chlorobenzylidene)-4-(5-((4-nitrophenoxy) methyl)-1, 3, 4-oxadiazol-2-yl) aniline (6c)
Yellow powder, 93% yield, m.p. 190–192 °C Rf = 0.72 (5% CH3OH: CHCl3). IR spectra (KBr) (v, cm−1):, 3060 (Ar-H), 2985 (CH aliphatic), 1570, 1382 (NO2), 1465 (CH2); 1HNMR (400 MHz, CDCl3): d = 5.00 (2H, s, CH2), 7.20–8.10 (12H, m, CH aromatic), 8.62 (1H, s, CH); MS: m/z (%) 436 (M+2H)+. Anal. Calcd for C22H15ClN4O4: C, 60.77; H, 3.48; N, 12.88. Found: C, 60.34; H, 4.15; N, 13.14.
2.1.4.4. N-(furan-2-ylmethylene)-4-(5-((4-nitrophenoxy) methyl)-1, 3, 4-oxadiazol-2-yl) aniline (6d)
Orange powder, 90% yield, m.p. 220–222 °C Rf = 0.55 (5% CH3OH in CHCl3). IR spectra (KBr) (v, cm−1), 3062 (Ar-H), 2990 (CH aliphatic), 1572, 1385 (NO2), 1460 (CH2); 1HNMR (400 MHz, CDCl3): d = 4.92 (2H, s, CH2), 6.60–8.15 (11H, m, CH aromatic), 7.65 (1H, s, CH); MS: m/z (%) 401 (M+Na)+. Anal. Calcd for C20H14N4O5: C, 61.54; H, 3.62; N, 14.35. Found C, 60.85; H, 4.07; N, 14.92.
2.1.5. General procedure for the preparation of 4 – ((2-(4-nitrophenoxy) methyl) − 1, 3, 4-oxadiazole nucleosides (8a-d)
Appropriate moieties of different monosaccharaides (1.5 gm, 1,8 gm, 1.8 gm and 1.8 gm, 0.01 mol respectively) and glacial acetic acid (1 ml) have been applied to the derivative of oxadiazole 4 (3.12 gm, 0.01 mol) in 35 ml EtOH. The resultant solution was heated in the presence of condenser for 5–8 h. The resultant product was purified by recrystallized by absolute ethyl acetate: methanol (1:1) in order to yield respectively 80–90% of the respective nucleosides.
2.1.5.1. 4-(4-N-Arabinfuranosylamino-phenyl) – 4 – ((2-(4-nitrophenoxy) methyl) − 1, 3, 4-oxadiazole (8a)
Pale orange crystal, 90% yield, m.p. = 265–267 °C, Rf = 0.55 (7% CH3OH: CHCl3). 1H NMR (400 MHz, DMSO‑d6) δ: 2.85 (1H, d, J = 2.5 Hz, H-1), 3.49 (2H, d, 2xOH,), 3.70 (1H, d, OH), 4.10 (1H, brs, NH), 4.63 (2H, s, 2H), 3.65–5.40 (4H, m, H-2, H-3, H-4, H-5), 6.45 – 7.60 (4H, m, Ar-H), 7.30 (2H, dd, J = 7.2 Hz, CH), 8.18 (2H, dd, J = 5.00 Hz, CH); MS: m/z (%) 444 (M)+.
2.1.5.2. 4-(4-N-Glactopyranosylamino-phenyl) – 4 – ((2-(4-nitrophenoxy) methyl) − 1, 3, 4-oxadiazole (8b)
Pale orange crystal, 88% yield, m.p. = 227–229 °C, Rf = 0.48 (7% CH3OH in CHCl3). IR spectra (KBr) (v, cm−1):, 3343 (OH), 3060 (Ar-H), 1630 (C N), 1570, 1382 (NO2), 1450 (CH2); 1H NMR (400 MHz, DMSO‑d6) δ: 3.65 (2H, d, 2xOH,), 3.59 (2H, d, 2xOH), 4.00 (1H, d, J = 2.5 Hz, H-1), 4.10 (1H, brs, NH), 4.60 (2H, s, 2H), 3.50–3.95(6H, m, H-2, H-3, H-4, H-5, H-6), 6.50 – 7.72 (4H, m, Ar-H), 7.22 (2H, dd, J = 7.2 Hz, CH), 8.10 (2H, dd, J = 4.9 Hz, CH); MS: m/z (%) 475 (M+H)+. Anal. Calcd for C21H22N4O9: C, 53.16; H, 4.67; N, 11.81. Found C, 53.34; H, 4.85; N, 11.63.
2.1.5.3. 4-(4-N-Glucopyranosylamino-phenyl) − 4 – ((2-(4-nitrophenoxy) methyl) − 1, 3, 4-oxadiazole (8c)
Pale brown crystal, 80% yield, m.p. = 294–296 °C, Rf = 0.75 (7% CH3OH in CHCl3). IR spectra (KBr) (v, cm−1):, 3347 (OH), 3045 (Ar-H), 1625 (C N), 1572, 1384 (NO2), 1470 (CH2); 1H NMR (400 MHz, DMSO‑d6) δ: 3.55 (2H, d, 2xOH,), 3.58 (2H, d, 2xOH), 3.92 (1H, d, J = 2.5 Hz, H-1), 4.05 (1H, brs, NH), 4.65 (2H, s, 2H), 3.53–3.91(6H, m, H-2, H-3, H-4, H-5, H-6), 6.52 – 7.75 (4H, m, Ar-H), 7.20 (2H, dd, J = 7.2 Hz, CH), 8.00 (2H, dd, J = 4.9 Hz, CH); MS: m/z (%) 476 (M+2H)+. Anal. Calcd for C21H22N4O9: C, 53.16; H, 4.67; N, 11.81. Found C, 53.25; H, 4.90; N, 11.93.
2.1.5.4. 4-(4-N-Mannopyranosylamino-phenyl) − 4 – ((2-(4-nitrophenoxy) methyl) − 1, 3, 4-oxadiazole (8d)
Pale orange powder, 85% yield, m.p. = 227–229 °C, Rf = 0.75 (7% CH3OH in CHCl3). IR spectra (KBr) (v, cm−1):, 3345 (OH), 3052 (Ar-H), 1632 (C N), 1570, 1380 (NO2), 1445 (CH2); 1H NMR (400 MHz, DMSO‑d6) δ: 3.52 (2H, d, 2xOH,), 3.60 (2H, d, 2xOH), 3.97 (1H, d, J = 2.5 Hz, H-1), 4.13 (1H, brs, NH), 4.62 (2H, s, 2H), 3.55–3.90 (6H, m, H-2, H-3, H-4, H-5, H-6), 6.49 – 7.62 (4H, m, Ar-H), 7.23 (2H, dd, J = 7.2 Hz, CH), 8.10 (2H, dd, J = 4.9 Hz, CH); MS: m/z (%) 476 (M+2H)+. Anal. Calcd for C21H22N4O9: C, 53.16; H, 4.67; N, 11.81. Found C, 53.45; H, 4.17; N, 12.02.
2.1.6. General procedure for the synthesis of acetylated nucleosides 9a-d
Equivalent amounts of nucleoside derivatives 8a-d (4.44 gm, 0.01 mol, 4.44 gm, 0.01 mol, 4.44 gm, 0.01 mol and 4.44 gm, 0.01 mol respectively) and acetic anhydride (6.02 gm, 0.01 mol) were dissolved in appropriate amount of anhydrous pyridine and the stirring of produced solution was occurred at 25 °C for 24 h. The blend is poured onto ice to create a light brown precipitates. The resulting products were purified to produce 80–85% of acetylated nucleosides of 9a-d.
2.1.6.1. 4-(2, 3, 5-Tri-O-acetyl)-N-arabinfuranosylamino-phenyl)- 4 – ((2-(4-nitrophenoxy) methyl) − 1, 3, 4-oxadiazole (9a)
Pale brown powder, 82% yield, m.p. = 194–196 °C, IR spectra (KBr) (v, cm−1):, 3400 (NH), 3050 (Ar-H), 1735 (COCH3), 1625 (C N), 1575, 1383 (NO2), 1445 (CH2); 1H NMR (400 MHz, DMSO‑d6) δ: 2.02–2.19 (9H, m, 3x COCH3), 4.05 (1H, brs, NH), 2.95–4.75 (5H, m, H-2, H-3, H-4, H-5), 4.76 (2H, s, CH2), 4.94 (1H, d, J = 5.5 Hz, H-1), 6.90–7.45 (8H, m, Ar-H); Anal. Calcd for C26H26N4O11: C, 54.74; H, 4.59; N, 9.82. Found C, 54.95; H, 4.83; N, 9.65.
2.1.6.2. 4-(2, 3, 5, 6-Tetra-O-acetyl)-N-galactopyranosylamino-phenyl)- 4 – (2-(4-nitrophenoxy) methyl) − 1, 3, 4-oxadiazole (9b)
Pale brown powder, 85% yield, m.p. = 201–203 °C, IR spectra (KBr) (v, cm−1):, 3400 (NH), 3050 (Ar-H), 1735 (COCH3), 1625 (C N), 1575, 1383 (NO2), 1445 (CH2); 1H NMR (400 MHz, DMSO‑d6) δ: 2.10–2.27 (12H, m, 4xCOCH3), 4.10 (1H, brs, NH), 2.92–4.78 (6H, m, H-2, H-3, H-4, H-5, H-6), 4.63 (2H, s, CH2), 5.10 (1H, d, J = 5.5 Hz, H-1), 6.96–7.41 (8H, m, Ar-H); MS: m/z (%) 642 (M)+. Anal. Calcd for C29H30N4O13: C, 54.21; H, 4.71; N, 8.72. Found C, 54.41; H, 4.87; N, 8.45.
2.1.6.3. 4-(2, 3, 5, 6-Tetra-O-acetyl)-N-glucoopyranosylamino-phenyl)- 4 – (2-(4-nitrophenoxy) methyl) − 1, 3, 4-oxadiazole (9c)
Pale brown powder, 80% yield, m.p. = 230–232 °C, IR spectra (KBr) (v, cm−1):, 3400 (NH), 3050 (Ar-H), 1735 (COCH3), 1625 (C N), 1575, 1383 (NO2), 1445 (CH2); 1H NMR (400 MHz, DMSO‑d6) δ: 2.12–2.30 (12H, m, 4xCOCH3), 4.05 (1H, brs, NH), 2.85–4.68 (6H, m, H-2, H-3, H-4, H-5, H-6), 4.63 (2H, s, CH2), 5.00 (1H, d, J = 5.5 Hz, H-1), 6.48–7.50 (8H, m, Ar-H); MS: m/z (%) 642 (M)+. Anal. Calcd for C29H30N4O13: C, 54.21; H, 4.71; N, 8.72. Found C, 54.65; H, 4.92; N, 8.85.
2.1.6.4. 4-(2, 3, 5, 6-Tetra-O-acetyl)-N-mannopyranosylamino-phenyl)- 4 - (2-(4-nitrophenoxy) methyl) − 1, 3, 4-oxadiazole (9d)
Pale brown powder, 85% yield, m.p. = 180–182 °C, IR spectra (KBr) (v, cm−1):, 3400 (NH), 3055 (Ar-H), 1735 (COCH3), 1630 (C N), 1575, 1383 (NO2), 1445 (CH2); 1H NMR (400 MHz, DMSO‑d6) δ: 2.07–2.24 (12H, m, 4xCOCH3), 4.00 (1H, brs, NH), 2.90–4.72 (6H, m, H-2, H-3, H-4, H-5, H-6), 4.60 (2H, s, CH2), 5.12 (1H, d, J = 5.5 Hz, H-1), 6.50–7.62 (8H, m, Ar-H); MS: m/z (%) 642 (M)+.
2.1.7. Preparation of α-Aminophosphonates 12 (a-d)
Equivalent amounts of hydrazide 3 (2.11 gm, 0.01 mol) triphenylphosphite (3.10 gm, 0.01 mol) and various aromatic aldehydes (pyridine-3-carboxaldehyde (1.07 gm, 0.01 mol), salisaldehyde (1.22 gm, 0.01 mol), 4-chlorobenzaldehyde (1.40 gm, 0.01 mol) and 5-methylfurfuraldehyde (1.10 gm, 0.01 mol) respectively were dissolved in CH3CN, the addition of few drops of perchloric acid occurred, later the stirring was occurred at 25 °C for 12 h. The solvent evaporated and then the residues of α-aminophosphonate derivatives were treated with diethyl ether and dried up at yields of 70–82%,12 (a-d).
2.1.7.1. Diphenyl ((2-(2-(4-nitrophenoxy) acetyl) hydrazinyl) (pyridin-3-yl) methyl) phosphonate (12a)
Dark brown gum, 80% yield, Rf = 0.45 (5% CH3OH: CHCl3). 1H NMR (400 MHz, DMSO‑d6) δ: = 3.85 (1H, brs, NH), 4.65 (2H, s, CH2), 5.88 (1H, s, CH), 7.21–8.22 (18H, m, Ar-H), 9.05 (1H, brs, NH); 13C NMR (100 MHz, CDCl3): d = 66.54 (CH2), 67.20 (CH—P—), 115.23, 120.35, 121.40, 123.67, 125.85, 130.15, 131.55, 134.33, 140.45, 148.22, 149.47, 150.37, 164.67 (Ar-CH), 167.55 (CONH); 31P NMR (162 MHz, CDCl3): δ: 19.73 (O P—CH—); EI-MS: m/z = 534 [M+]
2.1.7.2. Diphenyl ((2-hydroxyphenyl) (2-(2-(4-nitrophenoxy) acetyl) hydrazinyl) methyl) phosphonate (12b)
Brown gum, 82% yield, Rf = 0.45 (5% CH3OH in CHCl3). IR spectra (KBr) (v, cm−1):, 3290 (NH), 3420 (OH), 3050 (Ar-H), 2930 (CH aliphatic),1705 (C O), 1572, 1383 (NO2), 1445 (CH2); 1H NMR (400 MHz, DMSO‑d6) : δ = 3.78 (1H, brs, NH), 4.60 (2H, s, CH2), 5.10 (1H, s, OH), 5.85 (1H, s, CH), 7.22–8.18 (18H, m, Ar-H), 9.10 (1H, brs, NH); 13C NMR (100 MHz, CDCl3): δ = 61.43 (CH—P—), 66.63 (CH2), 115.27, 115.63, 120.36, 121.11, 121.32, 121.45, 125.87, 128.15, 128.29, 130.13, 134.33, 140.48, 150.24, 155.73, 164.26 (Ar-CH), 166.48 (CONH); 31P NMR (162 MHz, CDCl3): δ = 18.86 (O P—CH—); EI-MS: m/z = 550 [M+H]+.
2.1.7.3. Diphenyl ((4-chlorophenyl) (2-(2-(4-nitrophenoxy) acetyl) hydrazinyl) methyl) phosphonate (12c)
Brown gum, 70% yield, Rf = 0.45 (5% methanol in CHCl3). IR spectra (KBr) (v, cm−1):, 3295 (NH), 3050 (Ar-H), 2905 (CH aliphatic)1700 (C O), 1572, 1383 (NO2), 1445 (CH2); 1H NMR (400 MHz, DMSO‑d6) δ = 3.80 (1H, brs, NH), 4.60 (2H, s, CH2), 5.70 (1H, s, CH), 7.25–8.30 (18H, m, Ar-H), 8.97 (1H, brs, NH); 13C NMR (100 MHz, CDCl3): δ: = 66.63 (CH2), 68.02 (CH—P—), 115.27, 115.33, 120.45, 121.21, 121.25, 121.49, 125.98, 128.17, 128.40, 130.15, 134.41, 140.53, 150.26, 154.63, 164.25 (Ar-CH), 166.88(CONH); 31P NMR (162 MHz, CDCl3): δ = 19.22 (O P—CH—); EI-MS: m/z = 567 [M]+ Anal. Calc. for C27H23ClN3O7P: C, 57.10; H, 4.08; N, 7.40. Found C, 57.33; H, 4.59; N, 7.56.
2.1.7.4. Diphenyl ((5-methylfuran-2-yl) (2-(2-(4-nitrophenoxy) acetyl) hydrazinyl) methyl) phosphonate (12d)
Yellow gum, 75% yield, Rf = 0.45 (5% methanol in CHCl3). IR spectra (KBr) (v, cm−1):, 3295 (NH), 3050 (Ar-H), 2950 (CH aliphatic)1700 (C O), 1572, 1383 (NO2), 1445 (CH2), 1375 (CH3); 1H NMR (400 MHz, DMSO‑d6) δ = 2.2 (3H, s, CH3), 3.80 (1H, brs, NH), 4.65 (2H, s, CH2), 5.80 (1H, s, CH), 6.30–8.15 (16H, m, Ar-H), 8.85 (1H, brs, NH); 13C NMR (100 MHz, CDCl3): δ = 12.96 (CH3), 66.55 (CH2), 69.12 (CH—P—), 106.34, 108.14, 115.18, 115.22, 120.52, 121.32, 125.59, 130.23, 140.66, 150.28, 150.58, 150.75, 164.19 (Ar-CH), 166.38(CONH); 31P NMR (162 MHz, CDCl3): δ = 18.53 (O P—CH—); EI-MS: m/z = 539 [M]+ Anal. Calc. for C26H24N3O8P: C, 58.10; H, 4.50; N, 7.82. Found C, 58.41; H, 4.73; N, 7.63.
2.2. Microbiology
2.2.1. Bacterial isolates
Ethically approved microbes were used in this research, ethical committee of Taif Directorate of Health Affairs by the members in King Faisal Hospital in Taif. Taif, Saudi Arabia. Three multi-drug resistant bacterial strains. All strains were freshly subcultured on suitable media before beginning of the experiment.
2.2.2. Antimicrobial assay
The antimicrobial assay was conducted on synthesized compounds 4, 6b, 6d, 8a, 8c, 9b, 9d, 12a, 12b, 12c and 12d by using minor modifications on agar well diffusion method (Valgas et al., 2007). The inoculations in the Mueller agar plate of the measured bacteria (1 ml), which are inoculated at a standard 0.5 McFarland. The bottom of the wells was sealed with Muller Eight millimeters diameter sterile cork borer. A 20 µl of the synthesized compounds (50 mg/ml dimethylsulphoxide) were cultivated and put in incubator for 24 h at 37 °C. Amoxicillin (10 µg/ml) and Ciprofloxacin (5 µg/ml) for Pseudomonas auroginosa and E. coli. Vancomycin (10 µg/ml) and Amoxicillin (10 µg/ml) for S. aureus were included in the test. Finally, the experiment was repeated three times with duplicates and the inhibition zone was measured.
2.3. Computational study
2.3.1. Preparation of small molecule
Synthesized compounds to reduce their energy PM3 was used via MOPAC then DFT through B3LYP/6-311 G. The semi-empirical Hamiltonian molecular orbital calculation MOPAC16 kit was used for all Quantum chemical calculations were done. (Stewart, 2013), basis on implementation of MOE 2015 package (Molecular Operating Environment (MOE), density function theory in Gaussian 09 W program with the Becke3-Lee-Yang-parr (B3LYP) level using 6-311G* was employed. (Frisch et al., 2013). Geometry for molecular structures has been optimized to understand of the chemical structures, geometry for molecular structures has been optimized.
2.3.1.1. Selection of proteins structures
Docking tests for the active target site in DNA Gyrase B (ID: 4uro) and and Cathepsin B (ID: 1gmy) were evaluated using MOE 2015 (Version 2009.10). (Dale et al., 1999, Greenspan et al., 2003). Later, MOE was corrected for the structures with the errors of active sites. Subsequently hydrogens were added and partial charges (Amber12: EHT) were calculated. MOE Site Finder program was implied to identify the binding site of each receptors in protein; method based on alpha spheres (convex hulls) (Soga et al., 2007).
2.3.2. MOE stepwise docking methods
Crystal structures of enzymes were obtained by removal of Water and inhibitors molecule, addition of hydrogen atoms. The site finder module of MOE was used to generate alpha-site spheres. Triangular matcher placement method was used to generate optimized 3D structures of ligands. A random triplet of alpha sphere center was used to decide the pose in each iteration to generate by aligning ligand triplets of atoms in three alpha spheres defined at the receptor level. The poses developed by MMFF94x forcefield with treating solvation effects.
3. Results and discussions
3.1. Chemistry
The ester derivative 2 in 92% yield was obtained when P-nitrophenol was reacted with ethylchloroacetate and KOH in dry acetone under reflux. 95% acid hydrazide 3 yield was obtained, when synthesized ester 2 was reacted in ethanol reflux with hydrazine hydrate. The derivative of 1, 3, 4-oxadiazole 4 in 70% yield was prepared with reaction of hydrazide 3, p-aminobenzoic acid and phosphorous oxychloride under reflux. Compound 4 IR spectra showed the appearance of (NH2) group at 3460, 3505 cm−1 and (CO) group at 1645 cm−1 and disappearance of (NH) group. 1HNMR spectra peaks at 4.60, 6.05, 6.56–8.50 and 8.53 for CH2, NH2, eight protons of aromatic system and NH respectively; mass spectra with the molecular ion peak at 312 [M+] (Scheme 1).
Scheme 1.
Oxadiazole derivative with amino group 4 was reacted under reflux in ethanol with different aldehyde derivatives 5a-d and acetic acid under heat in the presence of condenser to give schiff bases 6a-d in 90–93% yields, the IR spectra of compounds 6a-d showed NO2 (1572, 1380 cm−1), CH2 (1465 cm−1), CH (aromatic) (3050–3070 cm−1) and OH group (3250 cm−1), 1HNMR spectra peaks around 4.60 for CH2 group, broad peak at 5.40. OH group had (CH) group of shiff bases around 8; the molecular ion peaks showed by mass spectra at 450 and 416 [M+] for 6a and 6b, 615 [M+2H]+ for 6c and 401 [M+Na]+ for 6d (Scheme 2) with no NH2 group.
Scheme 2.
Oxadiazole with amino group 4 reacted with different sugar (aldohexoses) derivatives 7a-d and acetic acid in absolute ethanol under reflux to give nucleosides 8a-d in 80–90% yields, the IR spectra of compounds 8a-d; (NO2) at 1570, 1380 cm−1, (CH2) at 1450 cm−1, (CH aromatic) at the range of 3050 to 3060 cm−1 and (OH) group at 3330 cm−1; 1HNMR spectra peaks for (NH) at 4.05–4.13, (CH2) at 4.60, the disappearance of (NH2), peaks for (OH) at 3.52 to 3.60 peaks (CH-Sugars) at 3.55–3.92, (CH-aromatics) at 6.52 to 7.75; the molecular ion peaks for 8a showed by mass spectra at 444 [M+], for 8b at 475 [M+H]+ and for 8c and 8d at 476 [M+2H]+. The nucleosides 8a-d were acetylated to give acetylated nucleosides 9a-d in 80–85% yields, the disappearance of peak for (OH) around 330 cm−1 and the appearance of peak for (COCH3) at 1735 cm−1 showed by IR spectra of compounds 9a-d, this change is due to that acetylation of the nucleosides 8a-d by acetic anhydride to the corresponding acetylated nucleosides 9a-d; the 1HNMR spectra showed that the disappearance of peaks for (OH) groups of nucleosides around 3.52 to 3.60 and appearance of peaks for (COCH3) groups at the range from 2.02 to 2.30 which were acetylated nucleosides 9a-d; mass spectra molecular ion peaks at 581 [M+Na]+ for 9a and 642 [M]+ for 9b, 9c and 9d (Scheme 3).
Scheme 3.
2-(4-Nitrophenoxy) acetohydrazide (3) reacted with triphenylphosphite (10), aldehyde derivatives 11a-d (pyridine-3-carboxaldehyde, salisaldehyde, p-chlorobenzaldehyde and 5-methylfurfuraldehyde respectively) and perchloric acid in acetonitrile gives α-aminophosphonate derivatives 12a-d in 70–82% yields. the IR spectra of 12a-d showed (CO) at 1705 cm−1, (NO2) at 1572, 1380 cm−1, (CH2) at1460 cm−1, and (OH) at 3420 cm−1; 1HNMR spectra peaks at 4.60 for CH2 group, (OH) at 5.10 group, (CH) group of shiff bases around 5.88, the appearance of aromatic protons around 6.30 to 8.22 and (NH) group around 9.05 to 9.10; 13C disappearance of (NH2) group. NMR spectra of the synthesized phosphonates 12a-d; (CH—P—) at 61.43 to 68.02; 31P NMR spectra of the synthesized derivatives 12a-d showed that the appearance of peaks for phosphorous of phosphonates (O P-CH–) at 19.73, 18.86, 19.22 and 18.53 for 12a, 12b, 12c and 12d respectively; mass spectra; molecular ion peaks at 534 [M+] for 12a, 550 [M+H]+ for 12b, 567 [M]+ for 12c and 539 [M]+ for 12d (scheme 4).
Scheme 4.
3.2. Microbiology
There is increasing high mortality rate related to increasing infections due to multidrug-resistant bacteria. When treating such infections, the therapeutical impact of widely used antibiotics frequently fails because of their transition to the antibiotics used by mechanisms of inductible resistance to antibiotics and regulatory bacterial gene mutations (Fowler et al., 2004). Twelve synthesized compounds (4, 6a, 6b, 8c, 8d, 9a, 9b, 9c, 12a, 12b, 12c and 12d) were subjected to antibiogram activity against three bacterial strains. The results showed that the substance 12a used in concentration (50 mg / ml dimethylsulphoxide). It was the most important destructive compound against E. coli, P. aeruginosa and S. Aureous with inhibition zone (35, 30 and 22 mm) respectively. E. coli isolates were sensitive to 4, 6a, 6b, 9a, 9b, 9c, 12b, 12c and 12d with zone size 20, 15, 13, 18, 22, 10, 24, 17 and 22 mm respectively. P. aeruginosa was sensitive to 4, 9a, 9b, 9c, 12b, 12c and 12d with zone size 16, 16, 18, 14, 20, 12, and 10 mm respectively. S. aureus was sensitive to 6a, 6b, 8c, 8d, 9a, 9b, 9c, 12b, 12c and 12d with inhibition zone size 12, 12, 16, 10, 24, 14, 18, 16, 15 and 18 mm respectively meanwhile, 12a showed the highest effect against three bacterial strains (Table 1). Previous studies show that multiple classes of flavonoids have antimicrobial activity and have been reviewed extensively (Batovska & Todorova, 2010). The activity of synthesized derivatives is most likely attributed to the existence of hydroxy groups in different nucleoside positions and the phosphorous movement. (Lewis & Jorgensen, 2005). Phosphonate qualities that are better suited to therapeutic use than widely used antibiotics. (Anandhi et al., 2014).
Table 1.
Antimicrobial activity of tested synthesized compounds and antibiotics on three clinical isolated bacteria. Nz: no zone. Nt: not tested.
Inhibition zone (mm) of 50 mg/ml | |||
---|---|---|---|
Compound no. | E. coli | P. aeruginosa | S. aureus |
4 | 20 | 16 | nz |
6a | 15 | nz | 12 |
6b | 13 | nz | 12 |
8c | nz | nz | 16 |
8d | nz | nz | 10 |
9a | 18 | 16 | 24 |
9b | 22 | 18 | 14 |
9c | 10 | 14 | 18 |
12a | 35 | 30 | 22 |
12b | 24 | 20 | 16 |
12c | 17 | 12 | 15 |
12d | 22 | 10 | 18 |
Ciprofloxacin | Nz | <6 | 24 |
Amoxicillin | Nz | Nz | <6 |
Vancomycin | Nt | Nt | 18 |
3.3. Docking studies
Docking experiment is most commonly used to design drug due to its efficiency in predicting the potency of molecule towards the reaction energy associated with potential binding conformations of an active site of biological strains; evaluation of target enzyme for evaluating the binding convergence at its catalytic site. The largest variation in the synthesized α-aminophosphonate derivative of Gibbs-free energy (after G) is the strongest binding convergence with the penicillin binding protein, involved in bacterial-cell wall maturation and cell-form development. The crystallographic structure of 2EX6 contained the amino acid residues with ampicillin as the attached ligand at the binding pocket. The synthesized compound 12a molecular docking research revealed (ΔG = −5.645 Kcal/mol) (Table 2). Amino acid residues; Ser420 and Ser398 has H-bond with target Compound (see Table 3).
Table 2.
. Computational study by energy scores (kcal/mol) derived from the MOE for synthesized compound 12 a.
PDB: 4uro | ||||||
---|---|---|---|---|---|---|
mol | E.dGE | E_conf | E_place | E.Int. | Eele | rmsd_ |
12 a | −5.645 | 183.702 | −84.595 | −10.953 | −18.486 | 3.006 |
PDB:1gmy | ||||||
mol | E.dGE | E_conf | E_place | E.Int. | Eele | rmsd_ |
12a | −6.657 | 210.339 | −82.132 | −10.086 | −21.099 | 1.889 |
Table 3.
Key interactions of the newly designed Ligand 12 a with active sites.
Ligand | Atom | Receptor | Amino acid residues | Interaction | Distance (A°) | E (kcal/mol) |
---|---|---|---|---|---|---|
PDB: 4uro | ||||||
12 a | N12 | OD2 | ASP57 | H-donor | 3.01 | −4.8 |
O10 | N | GLY125 | H-acceptor | 3.18 | −8.2 | |
O20 | N | GLY125 | H-acceptor | 3.45 | −1.1 | |
O39 | N | GLY85 | H-acceptor | 3.12 | −1.8 | |
PDB:1gmy | ||||||
12 a | O10 | SG | CYS29 | H-donor | 3.44 | −1.2 |
N12 | O | GLY74 | H-donor | 3.06 | −1.9 |
3.3.1. Structure activity relationship (SAR)
Compound 12a molecular docking results showed as antimicrobial. Due to pyridine moiety core in parent phosphonate derivative. Perpendicular arrangement of phosphonate and pyridine with Ser 420, this compound is stabilized in binding pocket. The ampicillin was used as refrence for binding into the active DNA Gyrase (Fig. 1). Hydrophilic amino acids serve as backbone in binding site (Fig. 2, Fig.3, Fig. 4). Due to hydrophobicity in nature is
Fig. 1.
The binding of ampicillin into the active DNA Gyrase.
Fig. 2.
The binding mode of 12a into the active DNA Gyrase.
Fig.3.
The binding mode of 12a into the active 1GMY.
Fig. 4.
The binding mode of 12a into the active 1NJE.
4. Conclusion
The nucleoside derivatives, α-aminophosphonates and arylidene analogues derived from 4-aminophenol were designed, prepared and elucidated by different spectroscopic analysis, physically studied by molecular docking of α-aminophosphonate derivative 12a showed most effective antibacterial activity against all bacterial strains in this study with inhibition zones (35, 30 and 22 mm) respectively and the theoretical binding with DNA of bacteria.
Acknowledgments
Acknowledgement
We acknowledge Taif University for Researchers Supporting Project number (TURSP- 2020/83), Taif University, Taif, Saudi Arabia.
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Footnotes
Peer review under responsibility of King Saud University.
References
- Amer H.H., Ali O.M., Salama A.A., El-gendy M.S., Houssin O.K. Synthesis of some new 1, 3, 4-oxadiazole derivatives bearing sugars and α-aminophosphonate derived from 4-nitrophenol as anticancer agents. Natl. J. Physiol. Pharm. Pharmacol. 2018;8(9):1275–1286. [Google Scholar]
- Anandhi D., Srinivasan P.T., Praveen G.K., Jagatheesh S. DNA fragmentation induced by the glycosides and flavonoids from C. coriaria. Int. J. Curr. Microbiol. Appl. Sci. 2014;3:666–673. [Google Scholar]
- Batovska D.I., Todorova I.T. Trends in utilization of the pharmacological potential of chalcones. Curr. Clin. Pharmacol. 2010;5(1):1–29. doi: 10.2174/157488410790410579. [DOI] [PubMed] [Google Scholar]
- Dale G.E., Kostrewa D., Gsell B., Steiger M., D'Arcy A. Crystal engineering: deletion mutagenesis of the 24 kDa fragment of the DNA gyrase B subunit from Staphylococcus aureus. Acta Crystallogr. D Biol. Crystallogr. 1999;55(9):1626–1629. doi: 10.1107/s0907444999008227. [DOI] [PubMed] [Google Scholar]
- Demirayak S., Karaburun A.C., Beis R. Some pyrrole substituted aryl pyridazinone and phthalazinone derivatives and their antihypertensive activities. Eur. J. Med. Chem. 2004;39(12):1089–1095. doi: 10.1016/j.ejmech.2004.09.005. [DOI] [PubMed] [Google Scholar]
- Ding Q.-B., Ou L., Wei D.-Z., Wei X.-K., Xu Y.-M., Zhang C.-Y. Enzymatic synthesis of nucleosides by nucleoside phosphorylase co-expressed in Escherichia coli. J. Zhejiang Univ. Sci. B. 2010;11(11):880–888. doi: 10.1631/jzus.B1000193. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dogruer D.S., Kupeli E., Yesilada E., Sahin M.F. Synthesis of new 2-[1(2H)-phthalazinon-2-yl]acetamide and 3-[1(2H)-phthalazinon-2-yl]propanamide derivatives as antinociceptive and anti-inflammatory agents. Arch. Pharm. Pharm. Med. Chem. 2004;337(6):303–310. doi: 10.1002/ardp.200200719. [DOI] [PubMed] [Google Scholar]
- EL-Hashasha M., Rizk S., El-Bassiouny F., Guirguis D., Khairy S., Guirguisb L. Facile synthesis and structural characterization of some phthalazin-1(2H)-one derivatives as antimicrobial nucleosides and reactive dye. Egypt. J. Chem. 2017;0(0):0. [Google Scholar]
- Fowler V.G., Jr., Sakoulas G., McIntyre L.M., Meka V.G., Arbeit R.D., Cabell C.H., et al. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J. Infect. Dis. 2004;190(6):1140–1149. doi: 10.1086/423145. [DOI] [PubMed] [Google Scholar]
- Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., et al., 2013. Gaussian 03, revision C. 02; Gaussian, Inc.: Wallingford, CT, 2004. There is no corresponding record for this reference. [Google Scholar].
- Greenspan P.D., Clark K.L., Cowen S.D., McQuire L.W., Tommasi R.A., Farley D.L., Quadros E., Coppa D.E., Du Z., Fang Z., Zhou H., Doughty J., Toscano K.T., Wigg A.M., Zhou S. N-Arylaminonitriles as bioavailable peptidomimetic inhibitors of cathepsin B. Bioorg. Med. Chem. Lett. 2003;13(22):4121–4124. doi: 10.1016/j.bmcl.2003.08.006. [DOI] [PubMed] [Google Scholar]
- Haikal A.Z., El Ashry E.S.H., Banoub J. Synthesis and structural characterization of 1-(d-glycosyloxy)phthalazines. Carbohydr. Res. 2003;338(22):2291–2299. doi: 10.1016/j.carres.2003.08.016. [DOI] [PubMed] [Google Scholar]
- Jordheim L.P., Durantel D., Zoulim F., Dumontet C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat. Rev. Drug. Discov. 2013;12(6):447–464. doi: 10.1038/nrd4010. [DOI] [PubMed] [Google Scholar]
- Lenz E.M., Wilson I.D., Wright B., Partridge E.A., Rodgers C.T., Haycock P.R., Lindon J.C., Nicholson J.K. A comparison of quantitative NMR and radiolabelling studies of the metabolism and excretion of Statil™ (3-(4-bromo-2-fluorobenzyl)-4-oxo-3H-phthalazin-1-ylacetic acid) in the rat. J. Pharm. Biomed. Anal. 2002;28(1):31–43. doi: 10.1016/s0731-7085(01)00637-9. [DOI] [PubMed] [Google Scholar]
- Lewis J.S., Jorgensen J.H. Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned? Clin. Infect. Dis. 2005;40(2):280–285. doi: 10.1086/426894. [DOI] [PubMed] [Google Scholar]
- Dudley E.d. Mass Spectrometry of Nucleosides and Nucleic Acids. CRC Press; 2009. pp. 163–194. [DOI] [Google Scholar]
- Sangshetti J., Pathan S.K., Patil R., Akber Ansari S., Chhajed S., Arote R., Shinde D.B. Synthesis and biological activity of structurally diverse phthalazine derivatives: a systematic review. Bioorg. Med. Chem. 2019;27(18):3979–3997. doi: 10.1016/j.bmc.2019.07.050. [DOI] [PubMed] [Google Scholar]
- Seley-Radtke K.L., Yates M.K. The evolution of nucleoside analogue antivirals: a review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. Antiviral Res. 2018;154:66–86. doi: 10.1016/j.antiviral.2018.04.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Soga S., Shirai H., Kobori M., Hirayama N. Use of amino acid composition to predict ligand-binding sites. J. Chem. Inf. Model. 2007;47(2):400–406. doi: 10.1021/ci6002202. [DOI] [PubMed] [Google Scholar]
- Stewart J.J.P. Optimization of parameters for semiempirical methods VI: more modifications to the NDDO approximations and re-optimization of parameters. J. Mol. Model. 2013;19(1):1–32. doi: 10.1007/s00894-012-1667-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Thomson J.M., Lamont I.L. Nucleoside analogues as antibacterial agents. Front. Microbiol. 2019;10:952. doi: 10.3389/fmicb.2019.00952. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tsesmetzis N., Paulin C.B., Rudd S.G., Herold N. Nucleobase and nucleoside analogues: resistance and re-sensitisation at the level of pharmacokinetics, pharmacodynamics and metabolism. Cancers. 2018;10(7):240. doi: 10.3390/cancers10070240. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Valgas C., Souza S.M.D., Smânia E.F., Smânia A., Jr Screening methods to determine antibacterial activity of natural products. Brazil. J. Microbial. 2007;38(2):369–380. [Google Scholar]
- Watanabe N., Kabasawa Y., Takase Y., Matsukura M., Miyazaki K., Ishihara H., Adachi H. 4-Benzylamino-1-chloro-6-substituted phthalazines: synthesis and inhibitory activity toward phosphodiesterase 5. J. Med. Chem. 1998;41(18):3367–3372. doi: 10.1021/jm970815r. [DOI] [PubMed] [Google Scholar]
- Yssel A.E.J., Vanderleyden J., Steenackers H.P. Repurposing of nucleoside-and nucleobase-derivative drugs as antibiotics and biofilm inhibitors. J. Antimicrobial. Chemother. 2017;72(8):2156–2170. doi: 10.1093/jac/dkx151. [DOI] [PubMed] [Google Scholar]